焦宇辰,中国医学科学院肿瘤医院研究员,博士生导师。1995年北京大学生命科学院协和医学预科,2003年在中国协和医科大学八年制临床医学专业获医学博士(MD)学位,2009年在Johns Hopkins大学获生物化学博士(PhD)学位。2010年进入Johns Hopkins大学Ludwig癌症研究所进行博士后研究,主要研究肿瘤基因组。2013年加入中国医学科学院肿瘤医院,从事肿瘤基础及转化研究。
焦宇辰
中国医学科学院肿瘤医院
长聘副教授
2019-05-31
生物学
细胞生物学
jiaoyuchen@cicams.ac.cn
焦宇辰,中国医学科学院肿瘤医院研究员,博士生导师。1995年北京大学生命科学院协和医学预科,2003年在中国协和医科大学八年制临床医学专业获医学博士(MD)学位,2009年在Johns Hopkins大学获生物化学博士(PhD)学位。2010年进入Johns Hopkins大学Ludwig癌症研究所进行博士后研究,主要研究肿瘤基因组。2013年加入中国医学科学院肿瘤医院,从事肿瘤基础及转化研究。
基于多种组学及生物信息学分析肿瘤分子改变时空异质性及肿瘤分子分型;基于CRISPR-Cas9协同致死筛选的功能基因组研究,发现针对驱动基因突变的新靶点、新药物;基于ctDNA多组学标志物的肿瘤液体活检技术在肿瘤早筛和疗效评估的应用。
1. Wang P#, Song Q#, Ren J#, Zhang W#, Wang Y, Zhou L, Wang D, Chen K, Jiang L, Zhang B, Chen W, Qu C*, Zhao H*, Jiao Y*. Simultaneous analysis of mutations and methylations in circulating cell-free DNA for hepatocellular carcinoma detection. Science Translational Medicine. 2022;14(672): eabp8704. (IF=19.319) 2. Ma Y#, Zhu Q#, Wang X#, Liu M, Chen Q, Jiang L, Chi Y, Zeng YX*, Zhao H*, Jiao Y*. Synthetic lethal screening identifies DHODH as a target for MEN1-mutated tumor cells. Cell Research. 2022, 32(6):596-599. (IF=46.297) 3. Zhao D#, Yue P#, Wang T#, Wang P#, Song Q, Wang J, Jiao Y*. Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer. Journal of Hematology Oncology. 2021, 14(1):164. (IF=23.168) 4. Fujikura K#, Hosoda W#, Felsenstein M#, Song Q#, Reiter JG, Zheng L, Beleva Guthrie V, Rincon N, Dal Molin M, Dudley J, Cohen JD, Wang P, Fischer CG, Braxton AM, No? M, Jongepier M, Fernández-Del Castillo C, Mino-Kenudson M, Schmidt CM, Yip-Schneider MT, Lawlor RT, Salvia R, Roberts NJ, Thompson ED, Karchin R, Lennon AM, Jiao Y*, Wood LD*. Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions. Gut. 2021, 70(5):928-939. (IF=31.793) 5. Zhu Q#, Ma Y#, Wei Z#, Li M, Zhang Y, Liu M, He H, Qu C, Cai J, Wang X*, Zeng Y*, Jiao Y*. AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma. Signal Transduction Targeted Therapy. 2021, 6(1):299. (IF=38.104) 6. Liang J#, Zhao H#, Diplas BH#, Liu S#, Liu J, Wang D, Lu Y, Zhu Q, Wu J, Wang W, Yan H, Zeng YX*, Wang X*, Jiao Y*. Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX-Mutant Cancers to WEE1 Inhibition. Cancer Research. 2020, 80(3):510-523. (IF=12.701) 7. Qu C#*, Wang Y#, Wang P#, Chen K#, Wang M#, Zeng H#, Song Q, Diplas BH, Tan D, Fan C, Guo Q, Zhu Z, Yin H, Jiang L, Chen X, Zhao H, He H, Wang Y, Li G, Bi X, Zhao X, Chen T, Tang H, Lv C, Wang D, Chen W, Zhou J, Zhao H, Cai J, Wang X, Wang S, Yan H, Zeng YX, Cavenee WK*, Jiao Y*. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. Proc Natl Acad Sci U S A. 2019, 116(13):6308-6312. (IF=9.412) 8. Huang J*, Xu B*, Mo H, Zhang W, Chen X, Wu D, Qu D, Wang X, Lan B, Yang B, Wang P, Zhang H, Yang Q, Jiao Y*. Safety, activity and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma. Clinical Cancer Research. 2018, 24(6):1296-1304. (IF=8.911, C100) 9. Zhang W#, He H#, Zang M#, Wu Q#, Zhao H#, Lu L#, Ma P, Zheng H, Wang N, Zhang Y, He S, Chen X, Wu Z, Wang X, Cai J, Liu Z, Sun Z, Zeng YX*, Qu C*, Jiao Y*, Genetic Features of Aflatoxin-associated Hepatocellular Carcinomas. Gastroenterology. 2017, 153(1):249-262. (IF=20.773) 10. Jiao Y#, Shi C#, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B*, Kinzler KW*, Hruban RH*, Papadopoulos N*. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011, 331(6021):1199-203. (IF=31.201, C100, ESI, R)皇冠足球90比分